Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00728689 · ClinicalTrials.gov registry record · Phase 1

Phase I Trial of an Investigational Small Pox Medication

A Phase 1 study, sponsored by SIGA Technologies.

Completed
Registry status
Phase 1
Development phase
12
Enrollment target

NCT00728689: Completed Phase 1 study, sponsored by SIGA Technologies.

NCT00728689 is a Phase 1 study that has completed, run by SIGA Technologies. The registered enrollment target is 12 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00728689, a Phase 1 study, has completed, sponsored by SIGA Technologies.

COMPLETED
Registry status
Phase 1
Development phase
12 participants
Enrollment target

Study Summary

The purpose of this study was to evaluate the pharmacokinetic parameters and safety of a single dose of ST-246 400mg Form I versus ST-246 400mg Form V capsules in fed normal healthy volunteers.

Primary Outcome

Mean terminal half-life (t½; hrs) for Forms I and V were calculated from \[plasma\] vs time profiles.

Interventions

  • DRUG ST-246 Days 1 - 3
  • DRUG ST-246 Days 11 - 13

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2008-08
Est. Completion 2008-10
Phase Phase 1
SIGA Technologies

8 total trials

What the finished NCT00728689 record still lists

NCT00728689 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower).

The record links to 0 conditions, and to 2 interventions - of which ST-246 Days 1 - 3 is the first listed.

NCT00728689 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00728689 about?

NCT00728689 is a clinical study titled "Phase I Trial of an Investigational Small Pox Medication". The purpose of this study was to evaluate the pharmacokinetic parameters and safety of a single dose of ST-246 400mg Form I versus ST-246 400mg Form V capsules in fed normal healthy volunteers.

What is the current status of trial NCT00728689?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2008-08. Estimated completion is 2008-10.

What interventions are being tested in trial NCT00728689?

The interventions under investigation include: ST-246 Days 1 - 3 (DRUG), ST-246 Days 11 - 13 (DRUG).

Who is sponsoring clinical trial NCT00728689?

This trial is sponsored by SIGA Technologies, which has 8 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00728689's enrollment target sits among peer trials

12 1852nd of 2000 higher than 90 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02602769 · 12 participants

    Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome

  • NCT02605421 · 12 participants · Phase 2

    Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

  • NCT02619448 · 12 participants · Early Phase 1

    Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC

  • NCT03311503 · 12 participants · Phase 1

    Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00728689, the US trial registry maintained by the National Library of Medicine. NCT00728689 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.